A review on the treatment of multiple myeloma with small molecular agents in the past five years

Zhenzhen Zhang,Xin Liu,Liyun Zhao,Yaru Zhou,Jianyou Shi,Weini Chen,Jinqi Li
DOI: https://doi.org/10.1016/j.ejmech.2021.114053
IF: 7.088
2022-02-01
European Journal of Medicinal Chemistry
Abstract:Multiple myeloma is currently incurable, and the incidence rate is increasing year by year worldwide. Although in recent years the combined treatment plan based on proteasome inhibitors and immunomodulatory drugs has greatly improved the treatment effect of multiple myeloma, most patients still relapse and become resistant to current treatments. To solve this problem, scientists are committed to developing drugs with higher specificity, such as iberdomide, which is highly specific to ikaros and aiolos. This review aims to focus on the small molecular agents that are being researched/clinically used for the treatment of multiple myeloma, including the target mechanism, structure-activity relationship and application prospects of small molecular agents.
chemistry, medicinal
What problem does this paper attempt to address?